Výsledky vyhledávání - "Rich Gedrich"

Data from A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors

Autor: T.R. Jeffry Evans, Emily Chan, Andrew Stephens, Rich Gedrich, Ronit Simantov, Srinivasu Poondru, Jordan Berlin, Jill Gilbert, Jeff Sosman, Laura Goff, Colin R. Lindsay, Igor Puzanov

Purpose: OSI-906 is a potent inhibitor of insulin-like growth factor-1 receptor (IGF1R) and insulin receptor (IR). The purpose of this study was to determine the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary activity of OSI-906 in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65e19dd22adf8ccff96fc405cb92cc57
https://doi.org/10.1158/1078-0432.c.6524550

Zobrazit plný text záznamu

Supplementary Fig. 1 from A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors

Autor: T.R. Jeffry Evans, Emily Chan, Andrew Stephens, Rich Gedrich, Ronit Simantov, Srinivasu Poondru, Jordan Berlin, Jill Gilbert, Jeff Sosman, Laura Goff, Colin R. Lindsay, Igor Puzanov

Supplementary Fig. 1. Patient disposition.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d6565efe604d2004f196627ca739b00
https://doi.org/10.1158/1078-0432.22460619.v1

Zobrazit plný text záznamu

Supplementary Figure 1 from Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors

Autor: Craig P. Carden, Stan B. Kaye, Scott M. Lippman, Rich Gedrich, Srinivasu Poondru, Ronit Simantov, Andrew W. Stephens, Faye M. Johnson, Salma Alam, Pilar Nava-Parada, Edward S. Kim, Robin L. Jones

Supplementary Figure 1: 79 patients enrolled in study.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::167e2c680e14cf8a4f9d144b55c0eec3
https://doi.org/10.1158/1078-0432.22461726.v1

Zobrazit plný text záznamu

Data from Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors

Purpose: We determined the maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics, and preliminary activity of OSI-906, a potent, oral, dual inhibitor of insulin-like growth factor-1 receptor (IGF1R) and insulin receptor (IR), in pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e470eb98d7b53b35b688ecf01cc18f5
https://doi.org/10.1158/1078-0432.c.6524880

Zobrazit plný text záznamu

Supplementary Tables 1 - 2 from Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors

Supplementary Materials Table 1. Ratio of area under the curve during the time interval between consecutive dosing (AUCtau) on day 3 to AUCtau on day 1 (schedule 1 [S1]) Table 2. Ratio of area under the curve during the time interval between consecut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::696da437ed7d3a7c82f68e9009a8e2af
https://doi.org/10.1158/1078-0432.22461723

Zobrazit plný text záznamu

Supplementary Materials from A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors

Autor: T.R. Jeffry Evans, Emily Chan, Andrew Stephens, Rich Gedrich, Ronit Simantov, Srinivasu Poondru, Jordan Berlin, Jill Gilbert, Jeff Sosman, Laura Goff, Colin R. Lindsay, Igor Puzanov

Supplementary Materials. Table 1. Drug-related adverse events (AEs) occurring during the initial 21 days of dosing in the expansion cohorts Table 2. Plasma OSI-906 pharmacokinetic parameters (expansion cohorts, Days 1 and 22) Table 3. Dose proportion

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccc2a73ae2442e3dddadb4447b8424b1
https://doi.org/10.1158/1078-0432.22460616

Zobrazit plný text záznamu

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Publikováno v: Cancer Research. 64:7099-7109

The RAS/RAF signaling pathway is an important mediator of tumor cell proliferation and angiogenesis. The novel bi-aryl urea BAY 43-9006 is a potent inhibitor of Raf-1, a member of the RAF/MEK/ERK signaling pathway. Additional characterization showed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b441c5007666c435b7d2f5e6a801cd57
https://doi.org/10.1158/0008-5472.can-04-1443

Zobrazit plný text záznamu

A phase 1, open-label study to evaluate the safety and pharmacokinetics of the anti ErbB3 antibody, KTN3379, alone or in combination with targeted therapies in patients with advanced tumors

Autor: Todd M. Bauer, Joseph Paul Eder, C. Sidor, Gerald Steven Falchook, Theresa LaVallee, Patricia LoRusso, Rich Gedrich, Jeffrey R. Infante

Publikováno v: Journal of Clinical Oncology. 33:2598-2598

2598 Background: KTN3379 is a human monoclonal antibody against a unique epitope of human epidermal growth factor receptor-3 (ErbB3) blocking ligand (neuregulin (NRG)) dependent and independent act...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2dbdf18111cfc2e473e88edbe85681ca
https://doi.org/10.1200/jco.2015.33.15_suppl.2598

Zobrazit plný text záznamu

News

Kolltan Pharmaceuticals Announces Presentations of Anti-KIT Antibody Preclinical Data at the 2016 American Association for Cancer Research (AACR) Annual Meeting

Autor: Kolltan Pharmaceuticals

Publikováno v: Business Wire (English). 04/20/2016.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Vyhledávací nástroje:

Upřesnit hledání